Drugs / Vaxigrip QIV
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07211152 Comparator | Oct 2025 → Mar 2026 overdue | influenza | Sinovac Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaxigrip QIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07211152 ↗ |
| Modality | Vaccine | “one dose of vaccine (0.5 mL) of Vaxigrip QIV” NCT07211152 ↗ |